Evidence map›Paper›PMID 40809929›Full record

ArticleWorld journal of gastroenterology2025

Flotillin-1 promotes the progression of hepatocellular carcinoma by activating TFE3-mediated Golgi stress response

Liang Zhang, Cheng-Zhi Bai, Jia-Yan Shan, Hong-Li Xue, Shu-Mei Zheng, Ya-Lun Chen, Shan-Hong Tang

Abstract read
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liang ZhangDepartment of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China.
Cheng-Zhi BaiDepartment of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China.
Jia-Yan ShanDepartment of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China.
Hong-Li XueDepartment of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China.
Shu-Mei ZhengDepartment of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China.
Ya-Lun ChenDepartment of Geriatric Medicine, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China.
Shan-Hong TangDepartment of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, Sichuan Province, China. shanhongtang@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is critical to explore effective therapeutic targets for improving the survival rate of patients with hepatocellular carcinoma (HCC). Although many studies have focused on flotillin-1 (FLOT1) as a lipid raft-associated protein that regulates the activation of some proteins or kinases to promote tumor cell survival and proliferation, few studies have explored the regulation of Golgi apparatus function.

aimTo investigate the molecular mechanism through which FLOT1 activates the Golgi stress response downstream of transcription factor E3 (TFE3), thereby promoting the progression of HCC.

methodsFLOT1 expression in HCC tissue, HCC cell lines, and nude mouse tumor models was assessed. The impact of FLOT1 silencing or its overexpression on the proliferation of HCC cells was studied. CCK-8, flow cytometry, and transwell assays were used to assess the proliferation, cell cycle, migration, and invasion abilities of HCC cells. A dual-luciferase reporter assay was used to study the effect of FLOT1 on the transcriptional activity of the downstream Golgi apparatus stress element promoter of TFE3. Western blotting, co-immunoprecipitation, and immunofluorescence staining were employed to detect relevant proteins.

resultsHigh FLOT1 expression was correlated with a poor prognosis in patients with HCC. The knockdown of FLOT1 suppressed the proliferation, migration, and invasion of HCC cells and promoted their apoptosis. Xenograft assays revealed that FLOT1 knockdown inhibited HCC tumorigenesis

conclusionFLOT1 recruits and inhibits mechanistic target of rapamycin complex 1/2, causing dephosphorylation and TFE3 nuclear translocation, thereby activating the Golgi stress response and further promoting the proliferation, migration, and invasion capabilities of HCC cells. These results underscore the potential of FLOT1 as a promising therapeutic target for HCC.

Indexed as

Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsCarcinoma, HepatocellularGolgi ApparatusLiver NeoplasmsMechanistic Target of Rapamycin Complex 2Membrane ProteinsAnimalsCell Line, TumorCell MovementCell ProliferationDisease ProgressionFemaleGene Expression Regulation, NeoplasticHumansMaleMechanistic Target of Rapamycin Complex 1Basic Helix-Loop-Helix Leucine Zipper Transcription FactorsflotillinsMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2Membrane ProteinsTFE3 protein, humanFlotillin-1Golgi stressHepatocellular carcinomaProliferationTranscription factor E3

Identifiers

PMID40809929
PMCPMC12344369

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.